{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:02:27Z","timestamp":1791165747281,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejca.2019.12.017","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T05:46:24Z","timestamp":1579758384000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Support of a molecular tumour board by an evidence-based decision management system for precision oncology"],"prefix":"10.1016","volume":"127","author":[{"given":"Mario","family":"Lamping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Benary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-656X","authenticated-orcid":false,"given":"Clemens","family":"Messerschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-0254","authenticated-orcid":false,"given":"Eric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1693-4444","authenticated-orcid":false,"given":"Thomas","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dido","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korinna","family":"J\u00f6hrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susen","family":"Burock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klinghammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Tinhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Beule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Yaspo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian T.","family":"Rieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.12.017_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib3","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","article-title":"Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses","volume":"20","author":"Tsimberidou","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.12.017_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2019.12.017_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00022","article-title":"Implementation and clinical utility of an integrated academic-community regional molecular tumor board","author":"Burkard","year":"2017","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.ejca.2019.12.017_bib6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41591-019-0442-2","article-title":"Molecular profiling in precision medicine oncology","volume":"25","author":"Le Tourneau","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00098","article-title":"Comparison of treatment recommendations by molecular tumor boards Worldwide","author":"Rieke","year":"2018","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.ejca.2019.12.017_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint consensus recommendation of the association for molecular pathology, American Society of clinical oncology, and College of American pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2019.12.017_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13073-016-0367-z","article-title":"Somatic cancer variant curation and harmonization through consensus minimum variant level data","volume":"8","author":"Ritter","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib13","first-page":"107","article-title":"A decision support framework for genomically informed investigational cancer therapy","author":"Meric-Bernstam","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.12.017_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.32358","article-title":"Variant Classification in precision oncology","author":"Leichsenring","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2019.12.017_bib15","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2019.12.017_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tranon.2016.03.001","article-title":"The path(way) less traveled: a pathway-oriented approach to providing information about precision cancer medicine on my cancer genome","volume":"9","author":"Taylor","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib18","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib19","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.12.017_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-014-3117-1","article-title":"A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer","volume":"147","author":"Jameson","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2019.12.017_bib21","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.ejca.2013.06.014","article-title":"Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center","volume":"49","author":"Wiesweg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.12.017_bib22","doi-asserted-by":"crossref","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib23","article-title":"Personalized medicine in the oncology clinic: implementation and outcomes of the Johns hopkins molecular tumor board","volume":"2017","author":"Dalton","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib24","article-title":"Prospective clinical study of precision oncology in solid tumors","volume":"108","author":"Sohal","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.12.017_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1634\/theoncologist.2014-0011","article-title":"Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel","volume":"19","author":"Johnson","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2019.12.017_bib26","doi-asserted-by":"crossref","first-page":"56491","DOI":"10.18632\/oncotarget.10606","article-title":"Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers","volume":"7","author":"Radovich","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.12.017_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2019.12.017_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1535-7163.MCT-15-0795","article-title":"Precision oncology: the UC san Diego moores cancer center PREDICT experience","volume":"15","author":"Schwaederle","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.12.017_bib29","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejca.2019.12.017_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","author":"Tredan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2017.35.15_suppl.101","article-title":"Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults","volume":"35","author":"Cobain","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib32","first-page":"1","article-title":"Personalized clinical decision making through implementation of a molecular tumor board: a German single-Center experience","author":"Hoefflin","year":"2018","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000339","article-title":"Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie","volume":"3","author":"Basse","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2019.12.017_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib35","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in Diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib36","article-title":"Impact of a biomarker-based Strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval","volume":"107","author":"Jardim","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.12.017_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000477157","article-title":"Cancer precision medicine: Why more is more and DNA is not enough","volume":"20","author":"Schutte","year":"2017","journal-title":"Public Health Genom"},{"key":"10.1016\/j.ejca.2019.12.017_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"Janne","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib39","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdx628","article-title":"SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer","volume":"28","author":"Soria","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.017_bib40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"Janne","year":"2017","journal-title":"Jama"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:16Z","timestamp":1760732776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919308767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":40,"alternative-id":["S0959804919308767"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Support of a molecular tumour board by an evidence-based decision management system for precision oncology","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}